PD-1／PD—L1抗体在非小细胞肺癌治疗中的研究现状  

Anti-PD-1 and anti-PD-L1 antibody in treatment of non-small cell lung cancer

作　　者：赵家义[1] 张蓉[1] 韩一平[1] 武宁[1] 

机构地区：[1]第二军医大学附属长海医院呼吸与危重症医学科,上海200433

出　　处：《国际呼吸杂志》2016年第8期616-619,共4页International Journal of Respiration

基　　金：国家自然科学基金青年科学基金项目（81201850）

摘　　要：程序性死亡因子1（programmed death-1，PD-1）存在于活化的T细胞和B细胞表面，是一种重要的免疫共抑制分子。当PD1与程序性死亡配体1／2（programmed death-ligand 1／2，PD-L1／2）结合后，可以引起一系列的免疫抑制作用，并使肿瘤逃避免疫破坏。阻断PD-1／PD-L1通路，则可能减弱其对免疫活性细胞的抑制作用，从而达到增强细胞免疫、杀灭肿瘤细胞的目的。目前大量研究证明PD-1／PD-L1抗体在非小细胞肺癌治疗中有显著的抗肿瘤活性。本文将对其研究现状加以综述。Programmed death-1 （PD-1）, an important immune co-inhibitory molecule, is present on the surface of activated T ceils and B cells. The binding of programmed death-ligand 1/2 （PDL1/2） to PD-1 generates an immunosuppressive effect and allows the tumor to evade immune destruction. Blocking PD-1/PD-L1 pathway could weaken its inhibition on immune ceils and enhance cellular immunity and kill tumor cells. At present, it has been demonstrated that anti-PD-1 and anti-PD-L1 antibodies have strong anti-tumor activity in the treatment of non-small cell lung cancer. This review summarizes the advancement of anti-PD-1/PD-L1 antibody in the treatment of non-small cell lung cancer.

关 键 词：程序性死亡因子1 程序性死亡配体1 免疫治疗 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]